Currently, surgical resection of the tumor is the standard of care and there is a lack of clinical studies supporting a particular chemotherapy regimen and/or post-surgical management specific for BARD1 mutation in breast cancer.The goals of this report are to emphasize the potential clinical significance of BARD1 mutation in breast cancer and to pursue a more tailored medical management to this mutation and genetic testing in family members to assess future risk of malignancy. Here, BARD1 is linked to breast carcinoma.